What is the difference between tri sprintec and sprintec

Undiagnosed abnormal uterine bleeding. Increased risk of cardiovascular events eg, stroke, MI esp. Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism, and during and after prolonged immobilization. Uncontrolled dyslipidemias. Gallbladder disease. Pregnancy-related cholestasis. History of depression; monitor and discontinue if serious depression recurs.

Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs. Patients should be instructed to review the patient information leaflet that accompanies the prescription each time it is filled. General recommendations for missed doses: If one dose is missed, the patient should take it as soon as she remembers and then take the next pill at the regular time as usual.

It may be necessary to take 2 tablets in one day. Some manufacturers recommend that a second method of non-hormonal contraception be used for at least 7 days after restarting the pills. If two doses in a row are missed, 2 tablets should be taken on both the day the missed doses are remembered and the following day.

The regular schedule should then be continued. A second method of non-hormonal contraception should be used for at least 7 days after restarting the pills.

If 3 or more doses in a row are missed, the patient should not take the missed pills. Recommendations for restarting the pills can be found in the patient information leaflet that accompanies the prescription each time it is filled. A second method of contraception should be used for at least 7 days after the pills are restarted. Use of norgestimate; ethinyl estradiol products, as with other contraceptive steroids, may result in clinical changes that influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.

Specific laboratory test interference has not been reported. Norgestimate; ethinyl estradiol does not protect against human immunodeficiency virus HIV infection or other sexually transmitted disease. Patients with known HIV infection or acquired immunodeficiency syndrome AIDS should be aware that the use of oral hormonal contraceptives will not prevent the transmission of HIV or other diseases to their partner s.

Surgery can increase the risk for thromboembolism from combined hormonal contraceptives. If feasible, discontinue norgestimate; ethinyl estradiol products at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism, and during and following any prolonged immobilization. Because of the increased potential for embolic risk, combined oral contraceptives COCs containing norgesimate; ethinyl estradiol are contraindicated in women who currently have diabetes mellitus and are over 35 years of age, diabetes mellitus with hypertension or with vascular disease or end-organ damage, or diabetes mellitus of greater than 20 years duration.

Patients with diabetes mellitus should be observed for changes in glucose tolerance when initiating or discontinuing estrogen therapy, since estrogen therapy may exacerbate diabetes. Altered glucose tolerance secondary to decreased insulin sensitivity has been reported. Women who are being treated for dyslipidemia should be followed closely if they elect to use combined oral contraceptives COCs.

Some progestogens may elevate LDL levels and may render the control of hyperlipidemia more difficult. Females with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs. Norgestimate; ethinyl estradiol is contraindicated in patients with migraine or other headache that is accompanied by focal neurological symptoms, such as aura, or women over age 35 with any migraine headaches.

COCs may cause an exacerbation of migraine or a change in headache patterns and should be used with caution in women with migraine.

Patients who complain of migraine with focal neurologic visual changes should be medically evaluated, and in some patients, such changes may indicate cerebrovascular events. Consistent with potential thrombotic effects of combined oral hormonal contraceptives COCs , there have been clinical case reports of retinal thrombosis with COC use. The COC should be discontinued if there is unexplained visual disturbance, partial or complete loss of vision, onset of proptosis or diplopia, papilledema, or retinal vascular lesions.

Appropriate diagnostic and therapeutic measures should be undertaken immediately. Estrogens can increase the curvature of the cornea; patients using contact lenses wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist. Norgestimate; ethinyl estradiol is contraindicated in patients with hypersensitivity to any of the product components. Ethinyl estradiol is generally contraindicated in patients who have a history of anaphylaxis or history of angioedema to the drug.

Cases of both anaphylactic reactions and angioedema have been reported in patients taking estrogens. Events have developed in minutes and have required emergency medical treatment. Exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema, which may be hormonally sensitive.

Given the increased prevalence of hypercoagulable states in patients with systemic lupus erythematosus SLE in particular antiphospholipid antibodies and lupus anticoagulant and the risk factors for thromboembolism, consider risks vs. Avoid COC use in SLE patients with a history of venous or arterial thrombosis or the presence of a hypercoagulable state. Combined hormonal oral contraceptive COC use has also been reported to induce, unmask, or exacerbate SLE; more data are needed.

Discontinue norgestimate; ethinyl estradiol if pregnancy is detected; there is no reason to continue combined oral hormonal contraceptives COCs during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects including cardiac anomalies and limb-reduction defects following exposure to COCs before conception or during early pregnancy.

For any patient who has missed two consecutive periods, pregnancy should be ruled out. If the patient has not adhered to the prescribed COC schedule, consider the possibility of pregnancy at the first missed period. Discontinue COC use if pregnancy is confirmed. Manufacturers recommend avoidance of combined hormonal oral contraceptives COCs if possible during breast-feeding until a mother has completely weaned her child.

Small amounts of oral contraceptive steroids estrogens and progestins have been identified in the milk of nursing mothers and a few reports of effects on the infant exist, including jaundice and breast enlargement.

Experts often recommend avoidance of estrogen-containing hormonal contraceptives, in the first 21 days postpartum due to maternal post-partum risks for thromboembolism following obstetric delivery, and the potential for COCs to interfere with the establishment of lactation. It is generally accepted that estrogen-containing combined hormonal contraceptives may be used after this period in healthy women without other risk factors; general monitoring of the infant for effects such as appetite changes, breast changes and proper weight gain and growth should occur.

Estrogens, including ethinyl estradiol EE , have been reported to interfere with milk production and duration of lactation in some women, particularly at doses of 30 mcg per day or more. One study found that lower dose oral combined contraceptives e. However, a systematic review concluded that the available evidence, even from randomized controlled trials, is limited and of poor quality; proper trials are needed.

Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.

Alternate contraceptive agents for consideration for use during breast-feeding include non-hormonal contraceptive methods and also progestin-only contraceptives e.

Norgestimate; ethinyl estradiol products are contraindicated in patients with hepatic disease. Because of the association with cholestasis and hepatic neoplasms, estrogens are contraindicated in the presence of hepatocellular cancer, hepatic adenoma, other liver tumors benign or malignant , or markedly impaired liver function e.

Discontinue use of norgestimate; ethinyl estradiol if jaundice develops during COC use. Steroid hormones may be poorly metabolized in patients with liver impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Patients with hepatitis C who are being treated with ombitasvir; paritaprevir; ritonavir, with or without dasabuvir, are also contraindicated to receive COCs.

During clinical trials with the hepatitis C combination drug regimen that contains ombitasvir; paritaprevir; ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal ULN , including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications. Discontinue COCs prior to starting hepatitis C therapy with the combination drug regimen ombitasvir; paritaprevir; ritonavir, with or without dasabuvir; COCs can be restarted approximately 2 weeks after completing treatment with the hepatitis C combination drug regimen.

Hepatic adenomas are associated with COC use. Each pill uses different combinations of synthetic hormones, and different doses and dosing patterns. There are low dose pills, monophasic, biphasic, and triphasic. And they all work great at preventing pregnancy! But they all interact with your body in different ways, so some of them tend to cause certain side effects more than others, and some will cause different side effects for you than they do for other women.

They have the same active ingredients as Sprintec, and are just as effective as Sprintec, although the pills may look slightly different and there might be differences in cost. But other than that, same stuff. Sprintec is a safe and effective combination birth control pill, and since it's a generic, it's pretty inexpensive, too.

Tri-Sprintec is one of the few birth control pills to have official FDA approval for use specifically to treat problem acne. All that upside could make it the best choice when you're choosing your birth control pill.

Contraception: X. Out-of-pocket spending for oral contraceptives among women with private insurance coverage after the Affordable Care Act. July Cochrane Library. Triphasic versus monophasic oral contraceptives for contraception. Published November 9, Cerel-Suhl S and Yeager B. Family Physician. Update on Oral Contraceptive Pills. Published November 1, Lortscher D et al. Journal of Drugs in Dermatology. Published June Armstrong C. American Family Physician. Published August 1, Effect of birth control pills and patches on weight.

Published January 29, Cooper D and Mahdy H. Oral Contraceptive Pills. Updated August 23,